These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Prediction of chronic allograft damage index of renal allografts using serum level of plasminogen activator inhibitor-1.
    Author: Chang HR, Yang SF, Lian JD, Lin CC, Wen MC, Chen YT, Jan YJ, Hsieh YS.
    Journal: Clin Transplant; 2009; 23(2):206-12. PubMed ID: 19220364.
    Abstract:
    BACKGROUND: Plasminogen activator inhibitor-1 (PAI-1) plays an important role in renal fibrosis. We conducted this study to examine whether serum PAI-1 has a role in predicting chronic allograft nephropathy (CAN). METHODS: Fifty kidney transplant recipients receiving graft biopsies were enrolled. The pathologic diagnoses were acute tubular necrosis (ATN; n = 12), borderline rejection (BR; n = 7), acute rejection (ACR; n = 12), CAN (n = 11), polyomavirus nephropathy (PVN; n = 3) and others (n = 5; glomerulopathy, n = 4; calcineurin inhibitor nephropathy, n = 1). The serum level of PAI-1 and chronic allograft damage index (CADI) score of each patient were determined. RESULTS: The CADI score of all patients was 4 (0-10) (median and range) and in each group was ATN 0.5 (0-4), BR 2.0 (1-4), ACR 4.0 (2-8), CAN 5.0 (4-10), PVN 7 (4-8) and others 2 (0-8). The serum PAI-1 level of each group was ATN 9.38 (2.35-14.52) ng/mL, BR 10.09 (0.61-18.06) ng/mL, ACR 11.08 (2.32-20.68) ng/mL, CAN 14.51 (3.66-21.12), PVN 14.79 (13.94-21.94) and others 16.35 (4.05-21.01) ng/mL. CADI score is associated with serum PAI-1 activity (r = 0.405, p = 0.003) and is inversely associated with serum creatinine (r = -0.348, p = 0.011), but not with estimated glomerular filtration rate (p = 0.124). CONCLUSION: Serum PAI-1 level has the potential to be a marker to predict CADI score, the quantitative score of CAN.
    [Abstract] [Full Text] [Related] [New Search]